arrow
G

Gianluca Masi

University of Pisa
H指数:58
被引数:2.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

First-line durvalumab and tremelimumab in poor-prognosis unresectable hepatocellular carcinoma: Phase IIIb single-arm SIERRA study

一线度伐利尤单抗和特瑞普利单抗在预后不良的不可切除肝细胞癌中的应用:IIIb期单臂SIERRA研究

2026-10-060
OAAI
Prognostic stratification of patients with biliary tract cancer treated with chemoimmunotherapy: A retrospective multicenter real-world study

胆道癌患者接受化疗免疫疗法后的预后分层:一项回顾性多中心真实世界研究

Cancer
IF5.1
2026-09-160
PRE
Prognostic Role of Adverse Events in a Worldwide Population of Patients with Biliary Tract Cancer Treated with Chemo-Immunotherapy

胆道癌患者接受化疗免疫疗法治疗后不良事件预测作用的全球人群研究

Cancers
IF4.4
2026-09-100
OA
Exploring the Role of Surgery After Systemic Therapy in Locally Advanced Biliary Tract Cancer: Outcomes From a Large Retrospective Multinational Real-World Cohort Treated With Cisplatin, Gemcitabine, and Durvalumab

探索系统性治疗后的手术治疗在局部晚期胆道癌中的作用:来自接受顺铂、吉西他滨和度伐利尤单抗治疗的大型回顾性跨国真实世界队列的结局

2026-08-150
PRE
Estimating the clinical benefit of metastases resection in liver-limited metastatic colorectal cancer: an IPD-based pooled analysis of nine randomized trials

评估肝转移性结直肠癌中转移灶切除的临床获益:一项基于IPD的九项随机试验的合并分析

2026-01-010
OA
Attenuation-based estimation of myocardial extracellular volume from ECG-ungated whole-body CT examinations as an early biomarker of chemotherapy-induced cardiotoxicity: preliminary findings

基于衰减的心肌细胞外体积估计:从非门控心电图全身CT检查作为化疗诱导的心脏毒性早期生物标志物的初步发现

2025-11-180
PRE
Durvalumab in Advanced Biliary Tract Cancer: Real-World Data From a Large Cohort of Patients Across Multiple International Centers

度伐利尤单抗在晚期胆道癌中的应用:来自多个国际中心大型患者队列的真实世界数据

2025-11-120
OAAI
Efficacy and Safety of Lenvatinib Versus Sorafenib in Recurrent HCC After Liver Transplant: A Multi-Center Real-World Study

仑伐替尼与索拉非尼在肝移植后复发性HCC中的疗效与安全性比较:一项多中心真实世界研究

2025-11-010
PRE
Cost–Benefit Analysis of Trans-Arterial Radio-Embolization with Y-90 Glass Microspheres Versus Drug-Eluting Bead Trans-Arterial Chemo-Embolization in Patients with Hepatocellular Carcinoma in Italy

经动脉放射性栓塞术(使用Y-90玻璃微球)与药物洗脱微球经动脉化疗栓塞术在意大利肝癌患者中的成本–效益分析

2025-10-060
OA
Genomic Pathway Alterations and Their Prognostic Impact in Biliary Tract Cancer: Insights from a Multinational Cohort Treated with Cisplatin, Gemcitabine, and Durvalumab

基因组通路改变及其在胆道癌中的预后影响:来自接受顺铂、吉西他滨和度伐利尤单抗治疗的跨国队列的见解

2025-10-030
PRE
Lenvatinib versus sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: the LEVIATHAN Study

伦伐替尼对比索拉非尼作为阿替利珠单抗联合贝伐珠单抗后肝癌的二线治疗:LEVIATHAN 研究

2025-09-230
OAAI
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine, and durvalumab: a large, real-life, worldwide population

接受顺铂、吉西他滨和度伐利尤单抗治疗的晚期胆道癌患者中分子改变的影响:一项大型、真实世界、全球性人群研究

2025-09-011
PRE
FOLFOXIRI/bevacizumab versus doublets/bevacizumab as initial therapy of unresectable liver-only, right-sided and/or RAS or BRAF mutated metastatic colorectal cancer: an individual patient data-based pooled analysis of randomized trials

FOLFOXIRI/bevacizumab与双药/bevacizumab作为不可切除的肝-only、右侧和/或RAS或BRAF突变转移性结直肠癌初始治疗的比较:一项基于个体患者数据的随机试验合并分析

2025-08-150
PRE
Atezolizumab plus bevacizumab versus Lenvatinib for patients with Barcelona clinic liver cancer stage B (BCLC-B) hepatocellular carcinoma (HCC): A real-world population

阿特珠单抗联合贝伐珠单抗与仑伐替尼对比用于巴塞罗那临床肝癌分期B期(BCLC-B)肝细胞癌(HCC)患者:一项真实世界人群研究

2025-06-090
PRE
The relative dose intensity of first-line FOLFOXIRI and FOLFOX/FOLFIRI both in combination with bevacizumab affects prognosis of metastatic colorectal cancer patients: A pooled analysis of TRIBE and TRIBE2 studies

FOLFOXIRI和FOLFOX/FOLFIRI两种一线方案,无论是否联合贝伐珠单抗,其相对剂量强度均会影响转移性结直肠癌患者的预后:TRIBE和TRIBE2研究的合并分析

2025-06-010
PRE
Efficacy and safety of atezolizumab/bevacizumab for hepatocellular carcinoma in a real-life prospective cohort: A 2024 update
2025-02-010
PRE
Atezolizumab plus bevacizumab as first-line treatment of unresectable hepatocellular carcinoma: interim analysis results from the phase IIIb AMETHISTA trial
2025-02-010
PRE
Statins in patients with advanced hcc treated with atezolizumab/bevacizumab: a propensity score-matched cohort analysis from arte an Italian prospective multicentric dataset
2025-02-010
PRE